GSK PLC Sponsored ADR (GSK) to Distribute Quarterly Dividend of $0.42 on January 8th

GSK PLC Sponsored ADR (NYSE:GSK) declared a quarterly dividend on Wednesday, October 29th. Stockholders of record on Friday, November 14th will be paid a dividend of 0.4171 per share by the pharmaceutical company on Thursday, January 8th. This represents a c) dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend is Friday, November 14th.

GSK has decreased its dividend payment by an average of 0.1%per year over the last three years. GSK has a dividend payout ratio of 33.7% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect GSK to earn $4.65 per share next year, which means the company should continue to be able to cover its $1.63 annual dividend with an expected future payout ratio of 35.1%.

GSK Stock Up 2.2%

Shares of NYSE GSK opened at $48.42 on Wednesday. The firm’s 50-day moving average is $43.14 and its two-hundred day moving average is $40.29. The company has a market capitalization of $98.31 billion, a PE ratio of 13.68, a price-to-earnings-growth ratio of 1.90 and a beta of 0.50. GSK has a 12-month low of $31.72 and a 12-month high of $48.48. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.22. The company had revenue of $11.35 billion during the quarter, compared to the consensus estimate of $8.21 billion. GSK had a return on equity of 51.07% and a net margin of 17.16%.GSK’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.50 earnings per share. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Equities analysts anticipate that GSK will post 4.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Dodge & Cox grew its holdings in shares of GSK by 14.9% during the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after purchasing an additional 10,210,921 shares during the last quarter. Fisher Asset Management LLC increased its position in GSK by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock valued at $1,203,395,000 after acquiring an additional 1,306,590 shares during the period. Primecap Management Co. CA raised its stake in GSK by 1.8% during the 1st quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock valued at $995,929,000 after acquiring an additional 446,360 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in GSK by 2.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock worth $299,163,000 after acquiring an additional 155,392 shares during the period. Finally, Royal Bank of Canada grew its stake in shares of GSK by 5.7% in the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock worth $293,692,000 after purchasing an additional 411,869 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.